甲状腺癌细胞系与患者来源异种移植物的标准化鉴定方法
针对甲状腺癌临床前模型中约40%存在重复、非甲状腺来源或非人源的问题,研究者提出了一套标准化鉴定流程,包括确定人源、排除淋巴瘤、DNA指纹与组织学比对、甲状腺标志物筛查、生物学行为检查及常见基因改变检测。应用该流程从294次原代培养中建立7株新甲状腺细胞系,从67次尝试中建立10例患者来源肿瘤异种移植,均通过验证。
要点
- 约40%的甲状腺癌细胞系模型存在重复、非甲状腺来源或非人源问题。
- 标准化鉴定流程包括人源确认、排除淋巴瘤、DNA指纹、标志物筛查、生物学行为及基因改变检测。
- 从294次原代培养中建立7株细胞系,从67次尝试中建立10例PDTX,均通过验证。
核心结论
- 该标准化细胞系和PDTX鉴定方法应能预防或检测未来的交叉污染,确保甲状腺癌研究仅使用有效的临床前模型。
研究设计与样本
- 基于作者推荐,采用标准化方法系统鉴定所有新生成的细胞系,包括人源确定、排除淋巴瘤、DNA指纹和组织学比较、甲状腺标志物筛查、生物学行为检查及常见甲状腺癌基因改变检测。
主要发现
- 从294次原代培养尝试中建立7株新甲状腺细胞系(LAM136、EAM306、SDAR1、SDAR2、JEM493、THJ529、THJ560)。
- 从67次尝试中建立10例患者来源肿瘤异种移植(PDTX;MC-Th-95、MC-Th-374、MC-Th-467、MC-Th-491、MC-Th-493、MC-Th-504、MC-Th-524、MC-Th-529、MC-Th-560、MC-Th-562)。
- 所有新细胞系和PDTX均通过作者方案成功验证。
关键数值与推荐
- 标准化鉴定包括(1)确定人源,(2)排除淋巴瘤,(3)DNA指纹和组织学比较以建立与假定组织来源的联系,(4)筛查两到三种甲状腺标志物以检查甲状腺分化,(5)检查生物学行为(生长速率、致瘤性),(6)检测常见甲状腺癌基因改变(TP53、BRAF、PTEN、PIK3CA、RAS、TERT启动子、RET/PTC、PAX8/PPARγ、NF1和EIF1AX)。
临床怎么用
- 该标准化方法可用于预防或检测细胞系和PDTX的交叉污染,确保甲状腺癌临床前研究使用有效模型。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the molecular underpinnings of thyroid cancer, preclinical cell line models are crucial; however, ∼40% of these have been proven to be either duplicates of existing thyroid lines or even nonthyroid-derived lines or are not derived from humans at all. Therefore, we set out to establish procedures and guidelines that should proactively avoid these problems, which facilitated the creation of criteria to make valid preclinical models for thyroid cancer research. DESIGN: Based on our recommendations, we systematically characterized all new cell lines that we generated by a standardized approach that included (1) determination of human origin, (2) exclusion of lymphoma, (3) DNA fingerprinting and histological comparisons to establish linkage to presumed tissue of origin, (4) examining thyroid differentiation by screening two to three thyroid markers, (5) examination of biological behavior (growth rate, tumorigenicity), and (6) presence of common thyroid cancer genetic changes (TP53, BRAF, PTEN, PIK3CA, RAS, TERT promoter, RET/PTC, PAX8/PPARγ, NF1, and EIF1AX). RESULTS: We established seven new thyroid cell lines (LAM136, EAM306, SDAR1, SDAR2, JEM493, THJ529, and THJ560) out of 294 primary culture attempts, and 10 patient-derived tumor xenografts (PDTXs; MC-Th-95, MC-Th-374, MC-Th-467, MC-Th-491, MC-Th-493, MC-Th-504, MC-Th-524, MC-Th-529, MC-Th-560, and MC-Th-562) out of 67 attempts. All were successfully validated by our protocols. CONCLUSIONS: This standardized approach for cell line and PDTX characterization should prevent (or detect) future cross-contamination and ensure that only valid preclinical models are used for thyroid cancer research.
引用
- Marlow LA, Rohl SD, Miller JL, et al. Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. J Clin Endocrinol Metab. 2018. PMID: 29846633. doi:10.1210/jc.2017-01845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。